دورية أكاديمية
Effective Treatment of Human Breast Carcinoma Xenografts with Single-Dose 211 At-Labeled Anti-HER2 Single-Domain Antibody Fragment.
| العنوان: | Effective Treatment of Human Breast Carcinoma Xenografts with Single-Dose 211 At-Labeled Anti-HER2 Single-Domain Antibody Fragment. |
|---|---|
| المؤلفون: | Feng Y; Department of Radiology, Duke University Medical Center, Durham, North Carolina., Meshaw R; Department of Radiology, Duke University Medical Center, Durham, North Carolina., Zhao XG; Department of Radiology, Duke University Medical Center, Durham, North Carolina., Jannetti S; Department of Radiology, Duke University Medical Center, Durham, North Carolina., Vaidyanathan G; Department of Radiology, Duke University Medical Center, Durham, North Carolina., Zalutsky MR; Department of Radiology, Duke University Medical Center, Durham, North Carolina zalut001@mc.duke.edu. |
| المصدر: | Journal of nuclear medicine : official publication, Society of Nuclear Medicine [J Nucl Med] 2023 Jan; Vol. 64 (1), pp. 124-130. Date of Electronic Publication: 2022 May 26. |
| نوع المنشور: | Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Society of Nuclear Medicine Country of Publication: United States NLM ID: 0217410 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1535-5667 (Electronic) Linking ISSN: 01615505 NLM ISO Abbreviation: J Nucl Med Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Reston, VA : Society of Nuclear Medicine Original Publication: [Chicago, Ill.] : S.N. Turiel & Assoc. |
| مواضيع طبية MeSH: | Single-Domain Antibodies*/therapeutic use , Single-Domain Antibodies*/metabolism , Breast Neoplasms*/radiotherapy , Breast Neoplasms*/metabolism, Humans ; Animals ; Mice ; Female ; Heterografts ; Receptor, ErbB-2/metabolism ; Cell Line, Tumor ; Treatment Outcome |
| مستخلص: | Single-domain antibody fragments (sdAbs) are attractive for targeted α-particle therapy, particularly with 211 At, because of their rapid accumulation in tumor and clearance from normal tissues. Here, we evaluate the therapeutic potential of this strategy with 5F7 and VHH_1028-2 sdAbs that bind with high affinity to domain IV of human epidermal growth factor receptor type 2 (HER2). Methods: The HER2-specific sdAbs and HER2-irrelevant VHH_2001 were labeled using N -succinimidyl-3- 211 At-astato-5-guanidinomethyl benzoate ( iso - 211 At-SAGMB). The cytotoxicity of iso- 211 At-SAGMB-5F7 and iso- 211 At-SAGMB-VHH_2001 were compared on HER2-expressing BT474 breast carcinoma cells. Three experiments in mice with subcutaneous BT474 xenografts were performed to evaluate the therapeutic effectiveness of single doses of iso- 211 At-SAGMB-5F7 (0.7-3.0 MBq), iso- 211 At-SAGMB-VHH_1028 (1.0-3.0 MBq), and iso- 211 At-SAGMB-VHH_1028 and iso- 211 At-SAGMB-VHH_2001 (∼1.0 MBq). Results: Clonogenic survival of BT474 cells was reduced after exposure to iso- 211 At-SAGMB-5F7 (D (© 2023 by the Society of Nuclear Medicine and Molecular Imaging.) |
| References: | J Mol Biol. 2005 Sep 23;352(3):597-607. (PMID: 16095608) Nucl Med Biol. 2019 Apr;71:32-38. (PMID: 31128476) Biochim Biophys Acta Rev Cancer. 2021 Apr;1875(2):188529. (PMID: 33647388) Nucl Med Biol. 2006 Apr;33(3):333-47. (PMID: 16631082) J Nucl Med. 2016 Oct;57(10):1569-1575. (PMID: 27230930) Nucl Med Biol. 2021 Sep-Oct;100-101:12-23. (PMID: 34144505) Nucl Med Biol. 2009 Aug;36(6):659-69. (PMID: 19647172) J Nucl Med. 2014 Apr;55(4):650-6. (PMID: 24578241) Mol Pharm. 2018 Apr 2;15(4):1457-1466. (PMID: 29502411) J Nucl Med. 2007 Jul;48(7):1190-6. (PMID: 17574991) Pharmaceuticals (Basel). 2019 Oct 15;12(4):. (PMID: 31618864) Eur J Nucl Med Mol Imaging. 2021 May;48(5):1371-1389. (PMID: 33179151) Cancers (Basel). 2020 Apr 21;12(4):. (PMID: 32326199) J Nucl Med. 2021 Oct;62(10):1468-1474. (PMID: 33547212) N Engl J Med. 2001 Mar 15;344(11):783-92. (PMID: 11248153) Sci Rep. 2022 Feb 22;12(1):3020. (PMID: 35194100) J Nucl Med. 2021 Nov;62(11):1624-1630. (PMID: 33637584) Clin Cancer Res. 2004 Dec 1;10(23):7834-41. (PMID: 15585615) Front Med (Lausanne). 2021 Jul 27;8:692436. (PMID: 34386508) Nucl Med Biol. 2013 Jan;40(1):52-9. (PMID: 23159171) Int J Radiat Oncol Biol Phys. 2007 Oct 1;69(2):572-9. (PMID: 17869670) Ther Adv Med Oncol. 2019 Mar 19;11:1758835919833519. (PMID: 30911337) Nat Rev Clin Oncol. 2020 Jan;17(1):33-48. (PMID: 31548601) J Nucl Med. 2022 Feb;63(2):259-267. (PMID: 34088772) Cancer Res. 2003 Aug 15;63(16):5084-90. (PMID: 12941838) J Control Release. 2020 Jan 10;317:34-42. (PMID: 31734445) Mol Cancer Ther. 2009 Oct;8(10):2861-71. (PMID: 19825804) Mol Pharm. 2020 Sep 8;17(9):3553-3566. (PMID: 32787284) J Nucl Med. 2014 Oct;55(10):1636-42. (PMID: 25157044) Expert Opin Biol Ther. 2016 Aug;16(8):1035-47. (PMID: 27145158) Nucl Med Biol. 2021 Jan;92:171-183. (PMID: 32448731) Mol Imaging Biol. 2017 Dec;19(6):867-877. (PMID: 28409338) Cancer Metastasis Rev. 2020 Sep;39(3):711-720. (PMID: 32399646) Mol Pharm. 2019 Aug 5;16(8):3524-3533. (PMID: 31268724) Nucl Med Biol. 2018 Jan;56:10-20. (PMID: 29031230) J Nucl Med. 2010 Feb;51(2):311-28. (PMID: 20080889) J Nucl Med. 2021 Aug 1;62(8):1097-1105. (PMID: 33277400) |
| فهرسة مساهمة: | Keywords: 211At; HER2; nanobody; radiopharmaceutical therapy; single-domain antibody fragment; α-emitter |
| المشرفين على المادة: | 0 (Single-Domain Antibodies) EC 2.7.10.1 (Receptor, ErbB-2) |
| تواريخ الأحداث: | Date Created: 20220526 Date Completed: 20230106 Latest Revision: 20230703 |
| رمز التحديث: | 20231215 |
| مُعرف محوري في PubMed: | PMC9841253 |
| DOI: | 10.2967/jnumed.122.264071 |
| PMID: | 35618478 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1535-5667 |
|---|---|
| DOI: | 10.2967/jnumed.122.264071 |